Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Baxter
Chinese Patent Office
Argus Health
QuintilesIMS
AstraZeneca
Federal Trade Commission
Healthtrust
Julphar

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,933,030

« Back to Dashboard

Which drugs does patent 8,933,030 protect, and when does it expire?

Patent 8,933,030 protects LINZESS and is included in one NDA.

This patent has eleven patent family members in eleven countries.
Summary for Patent: 8,933,030
Title:Treatments for gastrointestinal disorders
Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Fretzen; Angelika (Somerville, MA), Zhao; Hong (Lexington, MA), Kessler; Marco (Danvers, MA)
Assignee: Ironwwod Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/579,685
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,933,030
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,933,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-003 Jan 25, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. ➤ Sign Up
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,933,030

PCT Information
PCT FiledFebruary 17, 2011PCT Application Number:PCT/US2011/025274
PCT Publication Date:August 25, 2011PCT Publication Number: WO2011/103311

Non-Orange Book US Patents Family Members for Patent 8,933,030

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,073,571 ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,933,030

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 102869677 ➤ Sign Up
Denmark 2536742 ➤ Sign Up
Eurasian Patent Organization 201290799 ➤ Sign Up
European Patent Office 2536742 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Citi
Farmers Insurance
McKinsey
Mallinckrodt
Argus Health
Fish and Richardson
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.